GSK Pharma Slapped Rs 38.06 Cr Decree by Bombay Court in Legacy Property Dispute We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Mumbai: Global biopharma major GlaxoSmithKline Pharmaceuticals, best known in India for its blockbuster legacy brands Augmentin and Calpol, is charting a bold comeback in the country. The London-headquartered company, which has completed over a century in India’s pharma market, is plotting its most ambitious transformation in decades as it targets doubling its India revenue to…
After Years of Resistance, NPPA Finally Allows GSK to Discontinue Grisovin FP We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
GlaxoSmithKline Pharmaceuticals is re-entering India’s oncology market with the launch of Jemperli (dostarlimab) and Zejula (niraparib)— precision therapies indicated in the treatment of certain gynaecological cancers. GSK had exited the oncology segment globally about a decade ago after selling most of its cancer portfolio to Novartis. The launch of the drugs in India marks a…
GlaxoSmithKline Pharmaceuticals on Monday said it has made a foray into the oncology segment, bringing precision therapies for gynaecological cancers. The company has introduced advanced therapies Jemperli (dostarlimab) and Zejula (niraparib) in the country. “These therapies address a critical unmet need in gynaecological cancers in India and represent meaningful progress in women’s cancer care. With…
